The company said it expects to begin offering its Envisia classifier, for use in idiopathic pulmonary fibrosis diagnosis, to customers in 2021 as a kit-based test that runs on the nCounter system. As part of the deal, Veracyte also acquired NanoString Prosigna breast cancer prognostic test and in-development LymphMark lymphoma subtyping assay to expand its oncology portfolio.
Veracyte said it expects to realize a modest revenue contribution through the transaction of $6 million to $8 million in 2020, with a neutral impact to cash flow from the current business.
Price: 26.26, Change: -0.93, Percent Change: -3.54
|--Analyst Actions: BofA Securities Upgrades First So...|
|--Analyst Actions: DA Davidson Downgrades Prestige C...|
|Kazia Therapeutics Gets FDA Rare Pediatric Disease D...|
|--Analyst Actions: Morgan Stanley Cuts Alnylam Pharm...|
|Market Chatter: KKR Buying Rental Properties in Broo...|